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Abstract  
Background: Distribution of CYP2C9 and VKORC1 gene polymorphisms may vary significantly 
among different ethnic groups, and eventually influence the variation in drug metabolism or even 
failure. 
Objective: The aim of this study was to evaluate the prevalence of CYP2C9 and VKORC1 alleles 
in the healthy population of Republic of Macedonia compared to the global geographic data 
reported from different ethnic populations. Also, to genotype CYP2C9 and VKORC1 genes and 
eventually to divide individuals in poor, extensive, or intermediate metabolizer. 
Material and Methods: Blood samples were collected after signing written consent, DNA was 
isolated from peripheral blood, and CYP2C9 and VKORC1 genes were typed (n=124). Genotyping 
was performed by commercially available kits (GeneID GmbH, Strassberg, Germany, AID 
Diagnostica), based on the method of polymerase chain reaction with a subsequent hybridization. 
The population genetics analysis package, PyPop ver. 0.6.0, was used for analysis of the data. 
Results: The frequency of alleles varies from 0.931 for CYP2C9*3 to 0.109 for CYP2C9*2 
indicating common “wild type” allele in those genes. The frequency ranges spanned ~50% for each 
allele of VKORC1 gene, indicating no common “wild type” allele in this gene. Test of neutrality 
showed significant negative value for VKORC1 polymorphism that indicates balancing selection 
operating on the alleles at that locus. All polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 
showed a good fit with Hardy-Weinberg expectations. 
Conclusion: The results of polymorphic alleles of CYP2C9 and VKORC1 genes in Macedonian 
population can be used for the variation in drug metabolism studies as well for adapting dosage 
regimes for oral anticoagulant therapies. 
 
 
 
 
Introduction 
 The cytochrom P450 (CYP) family of heme 
monooxygenases comprise the most important group 
of Phase I enzymes. These enzymes oxidize a wide 
range of endogenous, as well as exogenous 
compounds. The cytochrome P450 gene family 
contains 60-100 different genes, of which only a small 
group is involved in drug and chemical 
transformations. The most important P450 isoenzyme 
is CYP3A4 (50% of the P450 metabolism) followed by 
CYP2D6 (20%), CYP2C9 and CYP2C19 (together 
15%). The remaining is carried out by CYP2E1, 
CYP2A6 and CYP1A2 [1].  
 The genes for CYP2D6, CYP2C9, CYP2C19 
and CYP2A6 are functionally polymorphic. Therefore, 
approximately 40% of human P450 dependent drug 
metabolism is carried out by polymorphic enzymes 
(for a list of all currently known cytochrome P450 gene 
alleles go to http://www.cypalleles.ki.se/ ) [2]. 
 There are 3 CYP2C9 alleles - CYP2C9*1 
allele is wild-type, but CYP2C9*2 and CYP2C9*3 are 
mutated alleles. In both mutated alleles, a point 
mutation leads to a substitution of an amino acid in 
the protein. In CYP2C9*2 an arginine at position 144 
is converted to cystein (R144C), in CYP2C9*3 an 
isoleucine at position 359 is converted to leucine 
(I359) Cytochrom P450 CYP2C9 catalyse the 
metabolism of important drugs such as phenytoin, 
tolbutamide, losartan, warfarin, and several NSAILs 
[3]. Interestingly, significant variation in distribution of 
polymorphic variants of the CYP450 genes is 
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documented among different populations worldwide 
[4-25].  The vitamin K epoxide reductase (VKOR) is a 
membrane protein in the endoplasmic reticulum, 
which catalyses the transformation of vitamin K 2,3-
epoxide into vitamin K hydroxyquinone, which is 
essential for the synthesis of factors II, VII, IX and XI 
of the coagulation system, as well as proteins C and 
S. The enzyme vitamin K epoxide reductase is 
pharmacodynamic target of oral anticoagulants and is 
encoded by the VKORC1 gene. 
 Macedonia is located in the Central Balkans, 
bordering Bulgaria, Greece, Albania, Serbia and 
Kosovo province, covering an area of 25,710 kms. 
According to the 2002 census, the country’s 
population was 2,022,577. Data on the declared 
ethnic affiliation from the 2002 census reported that 
64.1% of the population identify themselves as 
Macedonian, 25.17% as Albanian, 3.95% as Turks, 
2.66% as Roma, 1.78% as Serbs, 0.84% as Bosniacs, 
0.48% as Vlachs and 1.04% others [26]. The country 
seceded peacefully from Yugoslavia after an 
independence referendum, held in September 1991.  
 This is the first study of the diversity of 
polymorphisms of CYP2C9*2, CYP2C9*3 and 
VKORC1 in Macedonian populations. The aim of this 
study was to determine the frequencies of CYP2C9*2, 
CYP2C9*3 and VKORC1 alleles and genotypes and 
to compare them with populations for which similar 
data are available.  
 
Material and Methods 
 Population 
 Unrelated healthy male volunteers of 
Macedonian origin (n=124), between the age of 18-55 
years with a mean age of 36.43 ( 3.47) years, which 
are subjects of bioequivalnece studies, were included 
in the study. All individuals are of Macedonian origin, 
nationality, and residents of the geographical areas of 
different regions of the Republic of Macedonia. From 
each individual was obtained signed informed consent 
prior to his or her enrolment. The Ethical Committee of 
the Faculty of Medicine in Skopje has approved the 
study. After admission to the study, blood samples 
were collected from each subject (5 ml) into an EDTA 
tube, and the genomic DNA was isolated from 
peripheral blood leukocytes by the phenol-chloroform 
extraction method [27]. Samples were stored in 
Anthropology field of the Macedonian Human DNA 
Bank (hDNAMKD) [28]. 
 
 Typing methods 
 CYP2C9*2 (rs1799853), CYP2C9*3 
(rs1057910), and VKORC1 C1173T (rs 9934438) 
polymorphysims genotyping was performed by 
commercially available kits from GeneID GmbH, 
Strassberg, Germany. It is based on the method of 
polymerase chain reaction (PCR) with a subsequent 
hybridization. A multiplex PCR is first carried out with 
DNA isolated from whole blood. In this reaction, two 
fragments of the CYP2C9 gene and one fragment of 
the VKORC1 gene are amplified with specific biotin 
labelled primers. The amplified gene fragments are 
then characterized in a hybridization reaction with 
sequence-specific oligonucleotide probes (SSOP), 
which are immobilized on nitrocellulose (reverse 
hybridization). Each nitrocellulose strip has gene 
probes for the wild-type and mutated sequences of 
the tested gene fragments, as well as control zones. 
 
 Statistical methods 
 The population genetics analytics package, 
PyPop ver. 0.6.0 [29], was used for analysis of the 
gene data. Allele frequencies and expected Hardy 
Weinberg proportions (HWP) [30] for each single 
nucleotide polymorphisims (SNP) were determined. 
The exact test for genotype frequency deviation from 
HWP was calculated using the Arlequin 
implementation accessed via PyPop. Those SNPs 
that did not fit HWP were evaluated to determine 
wheather there was an excess of homozygotes or 
heterozygotes, or if any particular genotypes were 
significantly different fom expected frequencies by the 
Chi-square test. The Ewens-Watterson homozygozity 
test of neutrality with Slatkin’s p-values [31] was used 
to indicate any deviations from the hypothesis of 
neutral selection for each locus. P-value less than 
0.05 was taken as significant. 
 
Results 
 CYP2C9 and VKORC1 Alleles 
 Frequencies of polymorphic alleles, test of 
neutrality with Fnd statistic [Ewens-Watterson test of 
neutrality (EWN)], and Slatkin’s Exact p-value (SEPV) 
with p of F statistics in macedonian population are 
shown on the Table 1. The frequency of alleles varies 
from 0.931 for CYP2C9*3 to 0.109 for CYP2C9*2, 
indicating common “wild-type” allele in these genes. 
The frequency ranges spanned ~50% for each allele 
of VKORC1 gene, indicating no common “wild type” 
allele in this gene (Table 1). 
 
Table 1: Frequencies of polymoprhic alleles, test of neutrality 
with Fnd statistic (Ewens-Watterson test of neutrality (EWN)), 
and Slatkin’s Exact P. Value (SEPV) with p of F statistics in 
Macedonian population. 
Polymorphism 
Alleles 
Test of neutrality 
EWN SEPV 
Allele Number Frequency Fnd p of F 
CYP2C9*2 
*1 221 0.891 
-0.186 0.346 
*2 27 0.109 
CYP2C9*3 
*1 231 0.931 
0.210 0.430 
*3 17 0.069 
VKORC1 
C 134 0.540 
-1.995 0.027* 
T 114 0.460 
Statistically significant Fnd<0 indicates balancing selection; significant Fnd>0 indicates 
directional selection; *statistically significant. 
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 Test of neutrality showed negative values for 
Fnd statistics (Ewens-Watterson test of neutrality) for 
CYP2C9*2 and VKORC1 polymorphism (-0.186 and -
1.995, respectively), which indicates balancing 
selection operating on the alleles at that locus, but 
significantly different from 0 only for the VKORC1 
gene [Slatkin’s exact P value (SEPV) 0.346 and 
0.027, respectively]. Fnd was positive and none 
significantly differs from 0 for CYP2C9*3 (Fnd=0.210 
and p of F=0.430) (Table 1).  
 
 CYP2C9 and VKORC1 genotypes 
 Twenty-three individuals (18.6%) were 
heterozygous for CYP2C9*2, whereas 17 individuals 
(13.7%) were heterozygous for CYP2C9*3. There 
were two individuals (1.6%) which are homozygous 
for CYP2C9*2, but no individual was homozygous for 
CYP2C9*3. In addition, there were no individuals 
declared as heterozygotes (*2/*3). Thus, only 2 
individuals can be predicted as subjects to have the 
lowest CYP2C9 enzymatic activity, with respect to *2 
and *3; so they may be declared as PM (poor 
metabolizers).  
Table 2: Observed vs expected CYP2C9*2, CYP2C9*3 and 
VKORC1 genotypes, Hardy Weinberg proportions (HWP), and 
Guo Thompson Hardy Weinberg Output (GTHWO) in 
macedonian population. 
Polymor-
phism 
Geno-
type 
Obser-
ved 
number 
(n) 
Obser-
ved 
freq-
uency 
(%) 
Expec-
ted 
number 
(%) 
p-
value 
HWP 
p-
value 
GTHWO 
p-value 
CYP2C9*2 
*1/*1 
*1/*2 
*2/*2 
99 
23 
2 
79.8 
18.6 
1.6 
98.5 
24.1 
1.5 
0.829 
0.957 
& 
0.824 0.634 
CYP2C9*3 
*1/*1 
*1/*3 
*3/*3 
107 
17 
0 
86.3 
13.7 
0 
107.6 
15.8 
0.6 
0.995 
0.769 
& 
0.765 1.00 
VKORC1 
C/C 
C/T 
T/T 
37 
60 
27 
29.8 
48.4 
21.8 
36.2 
61.6 
26.2 
0.894 
0.838 
0.876 
0.772 0.858 
& Can not be calculated because expected <5, χ
2
 test. 
 
 Overall, the CYP2C9*2 allele had a frequency 
of 10.1%, whereas the CYP2C9*3 allele had a 
frequency of 6.8%. The observed genotype 
frequencies for both polymorphisms for CYP2C9 were 
consistent with Hardy Weinberg equilibrium (Table 2). 
 Sixty individuals (48.4%) were heterozygous 
for VKORC1 polymorphism, whereas 27 individuals 
(21.8%) had a homozygous genotype. The observed 
genotype frequencies for VKORC1 were consistent 
with Hardy Weinberg equilibrium (Table 2).  
 Observed versus expected genotypes for 
each SNP, Hardy-Weinberg proportion (HWP), and 
Guo and Thomson Hardy Weinberg Output (GTHWO) 
is given in the Table 3. All polymorphisms of 
CYP2C9*2, CYP2C9*3 and VKORC1 showed a good 
fit with HWP expectations (HWP p-value=0.824, 0.765 
and 0.772, respectively). In two instances, χ
2
 test 
cannnot be calculated because expected frequency 
was smaller than 5 (CYP2C9*2 *2/*2 and CYP2C9*3 
*3/*3). 
Table 3: Comparison of CYP2C9 allelic frequencies reported 
from different ethnic groups and different geographic regions. 
Population n 
CYP2C9 variant allele 
Refe-
rence Frequency, (p-value; NS-non significant) 
*1 *2 *3 
Caucasians 
Republic of 
Macedonia 
124 
0.831 
(referent) 
0.101  
(referent) 
0.068  
(referent) 
This 
study 
Spain 157 0.70(NS) 0.14(NS) 0.16 (0.001) [4] 
Italy 360 0.77(NS) 0.12(NS) 0.09(NS) [5] 
Slovenia 129 0.82(NS) 0.12(NS) 0.06(NS) [6] 
Croatia 200 0.74(NS) 0.16(NS) 0.09(NS) [7] 
Greece 283 0.79(NS) 0.13(NS) 0.08(NS) [8] 
France 151 0.77(NS) 0.15(NS) 0.08(NS) [9] 
Germany 266 0.81(NS) 0.11(NS) 0.08(NS) [10] 
Belgium 121 0.82(NS) 0.10(NS) 0.07(NS) [11] 
Sweden 430 0.82(NS) 0.17(NS) 0.07(NS) [12] 
Danmark 276 0.83(NS) 0.12(NS) 0.05(NS) [13] 
Britain 100 0.84(NS) 0.13(NS) 0.08(NS) [14] 
Russia 290 0.83(NS) 0.10(NS) 0.07(NS) [15] 
Hungary 332 0.86(NS) 0.11(NS) 0.09(NS) [16] 
America 100 0.85(NS) 0.08(NS) 0.06(NS) [17] 
Canada 114 0.81(NS) 0.03(0.007) 0.06(NS) [18] 
Turkey 499 0.79(NS) 0.11(NS) 0.10(NS) [10] 
Hispanic      
Mexican 
America 
169 0.86(NS) 0.08(0.029) 0.06(NS) [19] 
Brazil 331 0.86(NS) 0.07(0.017) 0.07(NS) [20] 
African      
Africa 993 0.99(NS) 0.02(0.001) 0.01(0.025) [21] 
African 
America 
100 0.98(NS) 0.01(1*10
-7
) 0.005(0.0002) [17] 
Egypt 247 0.82(NS) 0.12(NS) 0.06(NS) [22] 
Asian      
Vietnam 157 0.98 (NS) 0 (<0.0001) 0.02(0.0017) [23] 
Japan 218 0.98(0.037) 0 (<0.0001) 0.021(0.0008) [24] 
Korea 574 0.99(0.011) 0(<0.0001) 0.011 (<0.0001) [24] 
China 98 0.97(NS) 0 (<0.0001) 0.026(0.031) [24] 
South India 346 0.88(NS) 0.04 (3*10
-7
 ) 0.08(NS) [25] 
 
 Table 3 shows the distribution of frequencies 
of the CYP2C9 and VCORC1 variant alleles in the 
healthy population of Republic of Macedonia 
compared to data reported from various ethnic groups 
and global geographic regions.  
 Allelic frequencies of rs9934438 (1173C>T) 
polymorphism in VKORC1 in different countries/ 
regions are presented in Table 4. The lowest 
frequency of the VKORC1 CC genotype was reported 
in Chinese populations (1%, 1.11% and 2.9% 
respectively ) [33, 35, 39]. The highest frequencies for 
VKORC1 CC genotype were reported in Netherlands, 
Italy and USA (37.2%, 36.8%, and 36.1% respec-
tively). The frequency of VKORC1 CC genotype in 
Macedonians was similar to Caucasians (29.8%) 
(Table 4).  
Table 4: Allelic frequencies of rs9934438 (1173C>T) 
polymorphism in VKORC1 in different countries/regions. 
Reference SNP Genotypes Country/region Reference 
rs9934438  
(1173C>T) 
CC 
(%) 
CT 
(%) 
TT 
(%) 
  
 29.8 48.4 21.8 
Republic of 
Macedonia 
This 
paper 
 36.8 46.9 16.3 Italy [34] 
 36.1 50.7 12.7 USA [32] 
 34 49 17 France [41] 
 1 14 85 China [35] 
 1.11 
14.7
6 
84.1
3 
China [33] 
 2.9 15.7 81.4 China [39] 
 6 25 69 Hong Kong [36] 
 11 24 65 Egypt [37] 
 37.2 48 14.8 Netherlands [38] 
 
 Homozygous genotypes for VKORC1 TT 
were dominant in the yellow populations (85%, 69% 
and 65% in China, Hong Kong and Egypt, 
respectively). Dominant heterozygous VKORC1 CT 
genotypes were reported in all Caucasian populations 
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(Republic of Macedonia, Italy, USA, France and 
Netherlands) with frequencies between 46.9% and 
50.7 (Table 4). 
 
Discussion 
In this study we present the distribution of the 
common alleles of CYP2C9 that has been found to 
vary across populations and different ethnic groups. 
The extent of variation is directly related to the genetic 
distance between populations and the allele being 
examined [40].  
Results which are obtained from our study, showed 
that the allelic frequencies of CYP2C9*2 (10.1%) and 
CYP2C9*3 (6.8%) in tested population were similar to 
the general frequencies reported for the Caucasian 
population throughout Europe [41].  
Compared to the frequency of CYP2C9*3 found in the 
Spanish ethnic group (16.2%) [4] a significant 
interethnic difference was noticed.  
The CYP2C9*2 allele is not found in the Asian 
population, prevalent in approximately 15% in 
Caucasians and variable in populations with African 
ancestry (1-3.6% African Americans, 4.3% 
Ethiopians). CYP2C9*3 is estimated to 0.5-2.3% in 
Africans and 1.1-6.8% in Asians, but it is more 
common in Caucasians (3.3-17%) [41-44]. 
Several meta-analyses were published about the role 
of VKORC1 polymorphisms and different clinical 
conditions. To conduct a systemic review and meta-
analysis to investigate the relationship between mean 
daily warfarin dose (MDWD) and VKORC1 single 
nucleotide polymorphisms (SNPs), a total of 19 
studies were included in the meta-analysis. The 
frequencies of 1173TT and -1639 AA in Asian patients 
were higher than those in Caucasian and African 
populations. Sensitive analyses demonstrated that the 
impacts of gene polymorphism on warfarin dosage 
requirement were significantly different between 
Caucasian and Asian population, and the results of 
meta-analyses were stable and reliable [45]. 
Navigating the literature to determine how genotype 
will influence warfarin response in a particular patient 
is difficult, due to significant variation in patient 
ethnicity, outcomes investigated, study design, and 
methodological rigor. A paper was published where 
comprehensive search strategy was applied and 117 
studies included [46]. Primary outcomes were stable 
dose, time to stable dose and bleeding events. 
Assessing study quality highlighted significant 
variability in methodological rigor. Notably, there was 
significant evidence of selective reporting, of 
outcomes and analysis approaches [46]. 
 
Conclusion 
This study is the firsts on the distribution of the 
CYP2C9 and VKORC1 polymorphism in Macedonian 
population. This study shows that CYP2C9 and 
VKORC1 are polymorphic in the Macedonian 
population. Our data show that the distribution of 
CYP2C9 variant alleles frequencies are similar to the 
most of those reported for Caucasians of European 
descendant, but differ from those of North America 
Caucasians.  Results from this study suggest that the 
genetically determined capacity of CYP2C9 has to be 
taken into account in process of designing, conducting 
and evaluation of pharmacokinetics for investigational 
drugs [44].  
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